Organon & Co. (NYSE:OGN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Organon & Co. (NYSE:OGN) released its quarterly earnings results on Friday. The company reported $0.85 earnings per share for the quarter, missing analysts’ consensus estimates of $0.87 by ($0.02), FiscalAI reports. The company had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.

Organon & Co. Stock Performance

Shares of NYSE:OGN traded up $0.01 during trading on Friday, reaching $13.55. 2,689,351 shares of the company’s stock traded hands, compared to its average volume of 6,106,729. The company has a debt-to-equity ratio of 9.47, a current ratio of 1.97 and a quick ratio of 1.42. Organon & Co. has a 12 month low of $5.69 and a 12 month high of $13.60. The company has a 50 day moving average of $13.47 and a 200-day moving average of $10.38. The stock has a market capitalization of $3.56 billion, a P/E ratio of 14.58, a price-to-earnings-growth ratio of 1.25 and a beta of 1.54.

Analyst Upgrades and Downgrades

OGN has been the topic of several recent analyst reports. Zacks Research raised shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and increased their price target for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. Weiss Ratings upgraded Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, July 13th. Finally, BNP Paribas Exane reissued a “neutral” rating and set a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Five equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $11.40.

Insiders Place Their Bets

In other Organon & Co. news, SVP Lynette Holzbaur bought 26,448 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were purchased at an average price of $13.35 per share, with a total value of $353,080.80. Following the completion of the acquisition, the senior vice president directly owned 52,851 shares of the company’s stock, valued at approximately $705,560.85. The trade was a 100.17% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.62% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Organon & Co.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC acquired a new stake in shares of Organon & Co. during the 4th quarter worth approximately $47,000. Oxford Asset Management LLP bought a new stake in shares of Organon & Co. in the 4th quarter worth approximately $74,000. Empowered Funds LLC acquired a new position in Organon & Co. during the 4th quarter valued at approximately $74,000. Lazard Asset Management LLC acquired a new position in Organon & Co. during the 4th quarter valued at approximately $84,000. Finally, XTX Topco Ltd bought a new position in Organon & Co. during the 2nd quarter worth $107,000. 77.43% of the stock is currently owned by institutional investors and hedge funds.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.